Sep 1, 2023
Latest Presentation
Mar 17, 2023
Corporate Presentation
Recent Event
Mar 16, 2023
Fourth Quarter and Fiscal Year 2022 Results Webcast
The DPX Delivery Platform Enables Cancer Vaccines to be Clinically Viable
IMV Inc (Nasdaq, TSX: IMV) is a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on our proprietary DPX® delivery platform to treat solid and hematologic cancers.
Our lead DPX-based immunotherapy, maveropepimut-S (MVP-S) provides the clinical and molecular proof of concept of the potential of our DPX technology in multiple cancer indications. Across all studies, MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers.
DPX-SurMAGE, another DPX-based immune-educating therapy, is a dual-targeted immunotherapy evaluated in a Phase 1 clinical trial in bladder cancer which was initiated in early 2022.
We believe the DPX technology versatility enables several practical advantages to DPX-based immunotherapies. As such, we are leveraging this platform to build a series of unique immune-educating cancer immunotherapies.
Near Term Clinical Readout With Our Validated Platform
Our goal is to move MVP-S forward on the path to registration trials in r/r DLBCL and ovarian cancer, while leveraging our versatile DPX platform to build a diversified portfolio of cancer immunotherapies.
*The Breast and Non-muscle invasive bladder cancer studies are neoadjuvant studies that will provide critical molecular and cellular PoC in this new clinical setting.
| Program | H1 2023 | H2 2023 | |
|---|---|---|---|
| Maveropepimut-S (MVP-S) | DLBCL | ||
| Ovarian (AVALON) | |||
| Breast* | |||
| MVP-S and DPX-SurMAGE | Bladder* (NMIBC) | ||
*The Breast and Non-muscle invasive bladder cancer studies are neoadjuvant studies that will provide critical molecular and cellular PoC in this new clinical setting.